Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Friday, up 5.54% from the previous trading day, before settling in for the closing price of $5.05. Over the past 52 weeks, AMLX has traded in a range of $1.58-$7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 127.75% over the last five years. While this was happening, its average annual earnings per share was recorded 60.55%. With a float of $65.31 million, this company’s outstanding shares have now reached $89.08 million.
The firm has a total of 123 workers. Let’s measure their productivity. In terms of profitability, gross margin is 775.71%, operating margin of 16317.06%, and the pretax margin is 17255.66%.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 26.74%, while institutional ownership is 76.20%. The most recent insider transaction that took place on Mar 31 ’25, was worth 37,806. In this transaction Chief Financial Officer of this company sold 10,896 shares at a rate of $3.47, taking the stock ownership to the 290,988 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Medical Officer sold 12,425 for $3.47, making the entire transaction worth $43,082. This insider now owns 194,375 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.31% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 12.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.34 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Analysing the last 5-days average volume posted by the [Amylyx Pharmaceuticals Inc, AMLX], we can find that recorded value of 0.77 million was lower than the volume posted last year of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 59.10%. Additionally, its Average True Range was 0.38.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 92.54%, which indicates a significant increase from 75.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.55% in the past 14 days, which was lower than the 78.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.54, while its 200-day Moving Average is $4.03. Now, the first resistance to watch is $5.45. This is followed by the second major resistance level at $5.57. The third major resistance level sits at $5.80. If the price goes on to break the first support level at $5.10, it is likely to go to the next support level at $4.87. Should the price break the second support level, the third support level stands at $4.75.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 475.12 million has total of 89,141K Shares Outstanding. Its annual sales at the moment are 87,370 K in contrast with the sum of -301,740 K annual income. Company’s last quarter sales were recorded -660 K and last quarter income was -37,550 K.
